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ABSTRACT Mycoplasma pneumoniae is a common cause of community-acquired
pneumonia. The illumigene Mycoplasma Direct (iMD) DNA ampliﬁcation assay is a
qualitative in vitro test utilizing loop-mediated isothermal ampliﬁcation (LAMP) technology for the direct detection of M. pneumoniae DNA in respiratory specimens. The
iMD assay does not require the preextraction of nucleic acids from specimens, which
is a prerequisite step for the previously approved illumigene Mycoplasma (iM) assay.
The aim of this prospective multicenter study was to evaluate the performance characteristics of the newly developed iMD assay, compared with the iM assay. Subjects
with symptoms of upper respiratory illnesses suggesting M. pneumoniae infection
were enrolled at three sites in the United States. Respiratory specimens were obtained using dual throat swabs. One swab was tested with the iMD assay at each
enrollment site. Reference testing with the iM assay was performed by the manufacturer. Among 456 specimens tested, the iM reference method detected M. pneumoniae in 25 specimens (5.5%), while the iMD assay identiﬁed 34 specimens (7.5%)
as M. pneumoniae positive. There were 10 false-positive results and 1 false-negative
result with the iMD assay. The overall positive and negative agreement rates were
96.0% (95% conﬁdence interval [CI], 80.5 to 99.3%) and 97.7% (95% CI, 95.8 to
98.7%), respectively. The overall agreement rate was determined to be 97.6% (95%
CI, 95.7 to 98.6%). We conclude that the iMD test results were comparable to the iM
assay results. The removal of the DNA extraction step for the iMD assay simpliﬁes
testing, saves time, and reduces the costs of detecting M. pneumoniae from throat
swabs, compared to the iM assay.
KEYWORDS Mycoplasma pneumoniae, illumigene assay, LAMP technology

M

ycoplasma pneumoniae is a common cause of respiratory tract infections, especially in young adults and school-age children. Diagnosis of M. pneumoniae
infection based on a patient’s clinical presentation alone is difﬁcult and unreliable (1).
Prompt diagnosis is essential to initiate appropriate antibiotic therapy and infection
control.
Several methods are utilized for M. pneumoniae detection. Culture-based methods
are highly speciﬁc and sensitive but are time-consuming, and their sensitivity may vary
depending on laboratory skills (2, 3). Serology-based assays (complement ﬁxation assay,
enzyme-linked immunoassay, enzyme-linked immunosorbent assay, and microparticle
agglutination assay) are available. The limitations of serology-based assays include a
lack of sensitivity due to a delayed antibody response to M. pneumoniae infection, a lack
of response in older patients, highly prevalent background antibodies in healthy
individuals, and cross-reactivity with other Mycoplasma species (2, 4, 5). Rapid antigen
kits targeting speciﬁc proteins are also being utilized to diagnose M. pneumoniae. The
sensitivity of rapid antigen assays has been reported to vary from 60% to 90% (2, 6, 7).
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TABLE 1 Total subjects enrolled and M. pneumoniae prevalence across the three sites
No. of subjects
Site no. and location
Site 1, Florida
Site 2, Texas
Site 3, Missouri

Total
152
49
255

Total positive
4
4
26

M. pneumoniae
prevalence (%)
2.6
8.1
10.2

Total

456

34

7.5

Downloaded from http://jcm.asm.org/ on July 15, 2020 by guest

Nucleic acid ampliﬁcation testing (NAAT) assays have gained popularity due to
increased assay sensitivity (1, 2), which enables detection at an early stage of infection.
The loop-mediated isothermal ampliﬁcation (LAMP) assay is a NAAT assay that is simple,
easy to use (no thermocycler is needed), and highly sensitive, with a quick turnaround
time (2). The illumigene Mycoplasma (iM) assay (Meridian Bioscience, Inc., Cincinnati,
OH) utilizes LAMP technology for the detection of M. pneumoniae from throat and
nasopharyngeal swab specimens. The primers of this diagnostic kit target a 208-bp
DNA sequence found in the intracellular protease-like protein gene of the M. pneumoniae genome (1). A byproduct of the continuous isothermal ampliﬁcation reaction is
magnesium pyrophosphate. This white precipitate leads to turbidity in the reaction
mixture. The illumipro-10 incubator/reader monitors the changes in the absorbance
characteristics. Signiﬁcant changes in the absorbance of the reaction mixture indicate
the presence of the target gene. A study found the sensitivity and speciﬁcity of the iM
assay to be 100% and 99%, respectively, compared with the culture method (1).
Another recent study found both sensitivity and speciﬁcity of the iM assay to be 100%,
compared with the FilmArray respiratory panel (bioMérieux, France) (8).
The company manufacturing the iM assay recently developed an improved version,
the illumigene Mycoplasma Direct (iMD) assay, which does not require a Qiagen DNA
extraction step. The gene target and assay chemistry are identical for the iM and iMD
assays. This multicenter clinical trial compared the clinical performance of the iMD assay
with that of the iM assay, which requires nucleic acid extraction. This is the ﬁrst study
evaluating the performance of the iMD assay.
MATERIALS AND METHODS
Study design. This prospective multicenter clinical trial was conducted at three different sites
(Florida, Texas, and Missouri) across the United States. Patients with upper respiratory tract infections
that might be attributed to M. pneumoniae were enrolled after informed consent was obtained. Fresh
throat swab specimens from both male and female patients were collected between August 2015 and
January 2016. This study was designed to evaluate the performance of the newly improved iMD assay,
compared with the iM assay. The study protocols were approved by each hospital’s institutional review
board.
Specimens. Specimen inclusion criteria included (i) specimens collected from patients with symptoms of upper respiratory tract infections that might be attributed to M. pneumoniae or patients
suspected of having M. pneumoniae infection, (ii) two throat swabs from each subject enrolled, one
transported in nonnutrient transport medium and other in M4 medium, and (iii) written informed
consent provided by the subject. Specimen exclusion criteria included (i) specimens received in the
laboratory in unsatisfactory containers or conditions, (ii) multiple sets of specimens from the same
patient at different ofﬁce visits, (iii) specimens received in the laboratory with less than two throat swabs
per subject, and (iv) specimens stored in unapproved transport medium types or combinations. Demographic data collected at enrollment included age, gender, date of symptom onset, antibiotic use in past
4 weeks, and other medication use. No other clinical or radiological ﬁndings were recorded.
A total of 456 subjects at the three different sites were included in the study. A summary of the
subjects enrolled and M. pneumoniae prevalence across the three sites is provided in Table 1. Patients 3
weeks to 97 years of age with upper respiratory tract illnesses that might be attributable to M.
pneumoniae were included. A dual-swab (rayon tip) collection device was used to collect one specimen
per patient. One swab was stored in liquid Amies medium (catalogue no. 220105; Becton, Dickinson and
Company, Franklin Lakes, NJ, USA) and the second was stored in M4 transport medium (catalogue no.
12500; Thermo Fisher Scientiﬁc; Remel Products, Lenexa, KS, USA). Specimens were stored at 2 to 8°C
prior to testing. At each study site, specimens were deidentiﬁed and assigned a unique, site-speciﬁc,
study identiﬁer. Testing was performed with the iMD assay with one throat swab at each study site.
Operators at each study site tested external positive- and negative-control samples every day prior to
performing the iMD assay with the study samples. The second swab, in M4 medium, was shipped to the
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TABLE 2 M. pneumoniae prevalence according to age and gender across all three sites, as
determined with the iMD assay
No. of subjects
Site 1
(Florida)

Site 2
(Texas)

Site 3
(Missouri)

Total

Total
positive

M. pneumoniae
prevalence (%)

0
9
20
16
86
21

0
12
28
9
0
0

7
136
99
13
0
0

7
157
147
38
86
21

0
5
22
5
2
0

0.0
3.2
15.0
13.2
2.3
0.0

Gender
Male
Female

63
89

24
25

139
116

226
230

18
16

8.0
7.0

Total

152

49

255

456

34

7.5
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Age and gender
Age group
0–1 mo
2 mo to 2 yr
3–12 yr
13–21 yr
22–65 yr
⬎65 yr

manufacturer for testing with the iM assay. The results from the two assays were compared to determine
the performance of the iMD assay.
illumigene Mycoplasma Direct assay. The swab stored in red-capped nonnutrient liquid Amies
transport medium was utilized to perform the iMD assay, at the clinical site, within 72 h after sample
collection. Brieﬂy, the swab was inserted by breaking the swab handle in the SMP Prep tube provided
with the kit. The SMP Prep tube was vortex-mixed for 10 s. Five to 10 drops from the SMP Prep tube were
squeezed into a 1.5-ml heat treatment tube. The heat treatment tube was heated at 95°C for 10 min,
followed by 10 s of vortex-mixing. Fifty microliters of this heat-treated sample was transferred to the test
chamber as well as the control chamber of the illumigene test device. The device was closed, and all air
bubbles were removed by gently tapping the test device. The illumigene test device was inserted into an
illumipro-10 incubator/reader for direct detection of M. pneumoniae. Results were displayed on the
instrument as positive or negative at the conclusion of the run, in less than 1 hour.
illumigene Mycoplasma assay. Specimens stored in M4 medium were shipped (transport temperature, 2 to 8°C) to the company within 4 days after sample collection and were tested within 14 days. The
Qiagen QIAamp DSP DNA minikit was utilized to extract DNA from 150 l of the specimen. The
comparator iM assay was performed by the company according to the assay package insert.
Statistical analysis. (i) Descriptive statistics. Overall characteristics of the subjects enrolled and the
M. pneumoniae prevalence at each individual site were determined with reference to the iMD assay. M.
pneumoniae prevalence was also determined according to age and gender for each of the three sites.
(ii) Analytical statistics. Data tables (two by two) were utilized to determine the rates of positive and
negative agreement between the iM assay and the iMD assay. Analysis of the performance characteristics
(positive and negative agreement rates), with 95% conﬁdence intervals (CIs), was performed using the
Vassarstats website (http://vassarstats.net/clin1.html).

RESULTS
A total of 456 subjects with symptoms of upper respiratory tract illness, from three
different sites, were enrolled in the study. The highest prevalence was observed at the
Missouri site (10.2%), followed by the Texas site (8.1%) (Table 1). There was an
approximately equal distribution of male and female subjects enrolled in the study
(female, n ⫽ 230 [50.4%]; male, n ⫽ 226 [49.6%]) (Table 2). The median age of the
patients included in the study was 5 years (range, 0.06 to 97 years). The highest M.
pneumoniae prevalence was observed in the age group of 3 to 12 years (22/147
patients [15%]), compared to the rest of the study population (P ⬍ 0.001). The
association of age with M. pneumoniae prevalence has been documented in previous
studies (9–11). M. pneumoniae prevalence rates among female and male patients (7.0%
and 8.0%, respectively) were found to be comparable (P ⫽ 0.7). Detailed age- and
gender-speciﬁc prevalence rates across all sites are listed in Table 2.
Among the 456 specimens tested, the iMD and iM assays detected M. pneumoniae
in 34 specimens (7.5%) and 25 specimens (5.5%), respectively. There were 10 falsepositive specimens and 1 false-negative specimen detected by the iMD assay. The rates
of positive and negative agreement between the iMD assay and the iM assay were
96.0% and 97.7%, respectively. Discrepancy analysis was performed by repeat testing of
a second aliquot of the discrepant sample with the iM assay. Four of 10 false-positive
July 2018 Volume 56 Issue 7 e01930-17
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TABLE 3 Performance characteristics of the iMD assay, compared with the iM assay (with
Qiagen extraction)
No. of samplesa
iMD assay result
Positive
Negative

Positive iM
assay result
24
1c

Negative iM
assay result
10b
421

Total
34
422

Total

25

431

456

aOverall
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agreement, 97.6% (95% CI, 95.7 to 98.6%); positive agreement, 96.0% (80.5 to 99.3%); negative
agreement, 97.7% (95.8 to 98.7%).
bFour of 10 samples were identiﬁed as positive by the iM assay after testing with an additional frozen swab
collected from the patients for discrepancy analysis.
cRepeat testing with the iM assay, with the original patient sample and an additional frozen sample,
produced negative results.

specimens were identiﬁed as positive by the iM assay after retesting with an additional
frozen sample. Repeat testing of 1 false-negative specimen with the iM assay, using the
original patient sample and an additional frozen sample, produced negative results in
both cases.
Detailed performance parameters for all study subjects and speciﬁc parameters for
the study population are presented in Table 3. No invalid runs were observed during
the study. Results of standard-of-care tests for M. pneumoniae detection (an enzyme
immunoassay and PCR for the ﬁrst site, the iM assay for the second site, and the BioFire
FilmArray respiratory panel for the third site) were available for 70 of the 456 subjects
enrolled in the study, with 11 positive detections.
DISCUSSION
The objective of this multisite clinical trial was to evaluate the performance characteristics of the iMD assay, compared to the iM assay. This is the ﬁrst study evaluating
the performance of the iMD assay.
A previous study (8) in the United States compared the iM assay, the Prodesse
ProPneumo-1 assay (Hologic Gen-Probe, San Diego, CA, USA), and the Mycoplasma
pneumoniae P1 LightMix kit (TIB Molbiol, Howell, NJ, USA) with the FilmArray respiratory
panel (bioMérieux, France) for detection of M. pneumoniae from pediatric clinical
nasopharyngeal swab specimens. All of the three commercially available NAAT assays
had similar sensitivities, speciﬁcities (100%, 100%, and 96% for the iM assay, the
Prodesse assay, and the LightMix kit, respectively), and hands-on times. Another study
compared the iM assay with culture, using frozen respiratory specimens from adults
and children for whom historic culture results were available (1). The sensitivity and
speciﬁcity of the iM assay after discrepancy analysis were observed to be 100% and
99%, respectively. In our study, the overall rate of agreement between the iMD assay
and the iM assay was found to be 97.6%. Given the study results, it is expected that the
iMD assay will perform comparably, compared with the existing diagnostic platforms.
Current FDA-cleared sample-to-answer molecular methods for M. pneumoniae detection are the nested multiplex PCR panel by BioFire Inc. and standalone LAMP assays
(iM and iMD assays) by Meridian Bioscience, Inc. The iMD assay targets the intracellular
protease-like protein gene by utilizing LAMP technology (no thermocycler is needed)
and provides results in less than 1 hour. By comparison, the FilmArray respiratory panel
targets the tox gene for M. pneumoniae detection. Advantages of the iMD assay over
the FilmArray respiratory panel for M. pneumoniae detection are that both instrument
costs and costs per test are lower for the iMD test and the iMD assay has a higher
throughput (it can process 10 specimens, compared with a single specimen, at one
time), making it ideal for testing in an outpatient setting. One study evaluated the
performance of the FilmArray respiratory panel for detection of M. pneumoniae versus
a laboratory-developed real-time TaqMan PCR assay targeting the p1 gene (12) and
determined the positive agreement rate to be 100% (95% CI, 70.1 to 100%), which was
July 2018 Volume 56 Issue 7 e01930-17

jcm.asm.org 4

illumigene Mycoplasma Direct Assay Evaluation

Journal of Clinical Microbiology

ACKNOWLEDGMENTS
Funding for this study was provided by Meridian Bioscience, Inc.
We acknowledge the dedicated members of the enrollment team and laboratory
technicians at each site for helping with this study.

REFERENCES
1. Ratliff AE, Duffy LB, Waites KB. 2014. Comparison of the illumigene
Mycoplasma DNA ampliﬁcation assay and culture for detection of Mycoplasma pneumoniae. J Clin Microbiol 52:1060 –1063. https://doi.org/10
.1128/JCM.02913-13.
2. Parrott GL, Kinjo T, Fujita J. 2016. A compendium for Mycoplasma pneumoniae. Front Microbiol 7:513. https://doi.org/10.3389/fmicb.2016.00513.
3. Diaz MH, Winchell JM. 2016. The evolution of advanced molecular
diagnostics for the detection and characterization of Mycoplasma pneumoniae. Front Microbiol 7:232. https://doi.org/10.3389/fmicb.2016.00232.
4. Youn Y-S, Lee K-Y. 2012. Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr 55:42– 47. https://doi.org/10.3345/kjp.2012.55
.2.42.
5. Waites KB, Balish MF, Atkinson TP. 2008. New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections. Future
Microbiol 3:635– 648. https://doi.org/10.2217/17460913.3.6.635.
6. Miyashita N, Kawai Y, Tanaka T, Akaike H, Teranishi H, Wakabayashi T,
Nakano T, Ouchi K, Okimoto N. 2015. Diagnostic sensitivity of a rapid
antigen test for the detection of Mycoplasma pneumoniae: comparison
with real-time PCR. J Infect Chemother 21:473– 475. https://doi.org/10
.1016/j.jiac.2015.02.007.
7. Yamazaki T, Kuroki H, Itagaki T, Iwata S, Tateda K. 2015. Evaluation of a
rapid antigen detection kit targeting L7/L12 ribosomal protein for Mycoplasma pneumoniae. Kansenshogaku Zasshi 89:394 –399. https://doi
.org/10.11150/kansenshogakuzasshi.89.394.
8. Chou RC, Zheng X. 2016. A comparison of molecular assays for Mycoplasma pneumoniae in pediatric patients. Diagn Microbiol Infect Dis
85:6 – 8. https://doi.org/10.1016/j.diagmicrobio.2015.12.013.
9. Chen ZR, Yan YD, Wang YQ, Zhu H, Shao XJ, Xu J, Ji W. 2013. Epidemi-

July 2018 Volume 56 Issue 7 e01930-17

10.

11.

12.

13.

14.

15.

16.

ology of community-acquired Mycoplasma pneumoniae respiratory tract
infections among hospitalized Chinese children, including relationships
with meteorological factors. Hippokratia 17:20 –26.
Othman N, Isaacs D, Kesson A. 2005. Mycoplasma pneumoniae infections
in Australian children. J Paediatr Child Health 41:671– 676. https://doi
.org/10.1111/j.1440-1754.2005.00757.x.
Deﬁlippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, Di Marco E,
Cirillo C, Di Pietro P, Rossi GA. 2008. Epidemiology and clinical features
of Mycoplasma pneumoniae infection in children. Respir Med 102:
1762–1768. https://doi.org/10.1016/j.rmed.2008.06.022.
Pierce VM, Elkan M, Leet M, McGowan KL, Hodinka RL. 2012. Comparison
of the Idaho Technology FilmArray system to real-time PCR for detection
of respiratory pathogens in children. J Clin Microbiol 50:364 –371.
https://doi.org/10.1128/JCM.05996-11.
Touati A, Benard A, Hassen AB, Bébéar CM, Pereyre S. 2009. Evaluation of
ﬁve commercial real-time PCR assays for detection of Mycoplasma pneumoniae in respiratory tract specimens. J Clin Microbiol 47:2269 –2271.
https://doi.org/10.1128/JCM.00326-09.
Dumke R, Jacobs E. 2014. Evaluation of ﬁve real-time PCR assays for
detection of Mycoplasma pneumoniae. J Clin Microbiol 52:4078 – 4081.
https://doi.org/10.1128/JCM.02048-14.
Pillet S, Lardeux M, Dina J, Grattard F, Verhoeven P, Le Goff J, Vabret A,
Pozzetto B. 2013. Comparative evaluation of six commercialized multiplex PCR kits for the diagnosis of respiratory infections. PLoS One
8:e72174. https://doi.org/10.1371/journal.pone.0072174.
Loens K, Ieven M. 2016. Mycoplasma pneumoniae: current knowledge on
nucleic acid ampliﬁcation techniques and serological diagnostics. Front
Microbiol 7:448. https://doi.org/10.3389/fmicb.2016.00448.

jcm.asm.org 5

Downloaded from http://jcm.asm.org/ on July 15, 2020 by guest

comparable to the value of 96.0% (95% CI, 80.5 to 99.3%) for both iM and iMD assays
obtained in our study. We evaluated 25 true-positive M. pneumoniae isolates, compared
with 9 positive isolates utilized in the FilmArray respiratory panel study (12); this
resulted in relatively more robust estimates, as indicated by the 95% CIs.
Several studies conducted in Europe have compared various commercially available
NAAT assays for M. pneumoniae detection (13–15), and a summary of commercially
available NAAT assays for detection of M. pneumoniae was provided in a recent
minireview article (16). These NAAT assays need specialized trained personnel, expensive setups with thermal cycling ampliﬁcation platforms, and a molecular biology
facility. In contrast, the LAMP technology utilized in the iMD assay allows speciﬁc and
continuous DNA ampliﬁcation under isothermal conditions. The iMD assay is a sensitive
assay that does not require an additional DNA extraction step, making it faster and
more economical than other NAAT assays that require the DNA extraction step. Overall,
the iMD assay is a simple, convenient, and rapid molecular assay for detection of M.
pneumoniae from throat swab specimens.

